As KromoGEN Biotechnology, we offer solutions suitable for your needs with our clinical genetics product portfolio spread over a wide range of application areas from molecular genetic diagnosis to cytogenetics, molecular microbiology to pharmacogenomics, cancer genetics to prenatal diagnosis.

Molecular genetic methods are frequently used in the diagnosis and treatment monitoring of genetically based diseases. We have two solution partners in the field of molecular genetic diagnosis. These are PerkinElmer and Helix DNA Technologies.

PerkinElmer FragilEase™

Fragile X Syndrome is a common hereditary disease caused by an increase in CGG triple nucleotide repeats in the promoter region of the FMR1 gene located on the X chromosome. FMR1alleles are classified as normal, premutation and full mutation according to the number of CGG repeats.

The CE-certified FragilEase™ PCR assay is designed to amplify the entire CGG sequence in the FMR1promoter region. More than 900 repeats can be reliably detected by accurately amplifying triple nucleotide repeats using proprietary PCR components.

Heliks DNA Technologies, founded in Istanbul, Turkey, offers a wide product portfolio for the detection of many genetic-based diseases, from beta thalassemia to thrombophilia, from cystic fibrosis to familial mediterranean fever, with its minidarray-based products designed, developed and validated for the diagnosis of hereditary diseases.

Already in use in universities, hospitals and private genetic diagnostic laboratories across Turkey, these products are designed to be used with AppliedBiosystems genetic analyzers. You can find our full product portfolio here.

Heliks also offers validated sequencing kits for many diseases. Please contact us for more information.

Bringing the latest molecular techniques to cytogenetics laboratories, PerkinElmer is our partner in cytogenetics. PerkinElmer offers high detection rates, streamlined processes and products that are faster and more cost-effective. The molecular cytogenetics product line consists of complete workflow solutions consisting of consumables, instruments and corresponding software packages.

Oligonucleotide-based microarray systems provide high resolution in detecting copy number changes in the genome. Although traditional karyotyping methods such as FISH or G-banding are frequently used techniques for the detection of chromosomal aberrations, these methods are disadvantageous in terms of resolution, working with large numbers of samples, speed and cost. As a result, arrayCGH methods have become the preferred methods for the detection of submicroscopic deletions and duplications in the genome in a single experiment.

In the ArrayCGH method, oligonucleotides are fixed on glass slides. Differently labeled sample and reference DNAs are hybridized with immobilized probes. In this way, copy number changes in the genome can be detected in a single experiment and with high resolution.

PerkinElmer offers complete product solutions consisting of CGHOligo Arrays, hybridization instruments, scanner and Genoglyphix analysis software.

You can contact us for more information.

PerkinElmer CGX™ Oligo Arrays

CGX Oligo Arrays are microarrays designed, developed and validated for the detection of small genetic anomalies associated with learning disabilities and dysmorphic traits. The oligonucleotide probes in the CGXTM, CGXTMHD and CGXTMSNP arrays include more than 245 cytogenetically linked regions, as well as genes involved in development, pericentromeric regions and sub-telomere regions.

Almost all anomalies detected with CGX Oligo Arrays can be visualized by FISH. FISH confirmation can be used to identify structural changes or the source of any alteration. With the ability to order unlabeled BACklon for confirmation, PerkinElmer offers a complete solution package that includes both detection and confirmation.

PerkinElmer CGX™ Onco Arrays

CGX™ Onco Arrays are designed, developed and validated for the detection of small genetic changes and alterations in tumor genes associated with hematological diseases such as leukemia or lymphoma. These arrays cover the entire genome and provide higher resolution in specific regions associated with cancer. At the same time, by combining CGH and SNP probes in the same array, both copy number changes and genomic abnormalities that do not affect copy number can be detected in a single experiment.

PerkinElmer CGX™ OncoArrays and consumables enable faster and more accurate detection of genomicomalies in oncology samples with the Oncoglyphix® software package.

PerkinElmer BACs-on-Beads™ (BoBs) The technology offers significant advantages such as ease of use, low sample volumes and short turnaround times.

DNA probes from bacterial artificial chromosomes (BAC; bacterial artificial chromosome) Luminex® xMAP® BoBs technology, in which fluorescent molecules are fixed to coded beads, enables rapid detection of copy number changes in targeted genomic regions with small amounts of DNA sample. BACs-on-Beads technology supports molecular karyotyping of large numbers of samples, helping to increase laboratory throughput and better utilization of resources.

BoBs technology PerkinElmer Constitutional BoBs™ and KaryoLite BoBs™ products are utilized. BoBs tests Luminex® 100/200™ is performed using the device. Measurements from the device BoBsoft™ is analyzed with the help of software.

Constitutional BoBs™

Constitutional BoBs products are used to detect copy number variations on five chromosomes. Abnormalities at 9 specially selected microdeletion sites can also be analyzed. This test uses 5 markers each to screen for aneuploidy on chromosomes 13, 18, 21, X and Y, and 4-8 independent markers for each of the additional target regions.

Detailed information about the product in our brochure you can find.

KaryoLite BoBs™

KaryoLite BoBs was developed to detect aneuploidies on 24 chromosomes in a single test. The product covers 1-22 and the p and q arms of the X and Y chromosomes (q arms of the acrocentric chromosomes). Based on BACs-on-Beads technology, it consists of BAC DNA fixed in polystyrene microspheres that can be detected with Luminex® systems.

The KaryoLite BoBs product can be used with 50 ng of DNA extracted from amniotic fluid, chorionic villi or fetal tissues. It does not require cell culture, providing a clear advantage over traditional cytogenetic techniques.

Detailed information about the product in our brochure you can find.

Luminex 100/200 System

The Luminex 100/200 System is based on the measurement by flow cytometry of signals from xMAP microspheres, which form the basis of BACs-on-Beads products. The system requires very low sample volumes and allows 100 analytes to be measured in a single microplate well. The system consists of a Luminex 100/200 analyzer, LuminexXYPplate platform, LuminexSD liquid delivery system, software and PC.

Please contact us for further information.

Luminex 100/200 System

BoBsoft™ Analysis Software

BoBsoft™ analysis software is used for data analysis in products based on BACs-on-Beads chemistry. It receives multiplex measurement data from Luminex® instruments, performs calculations for the user to determine the quality of the experiments and determines patient results in comparison with normal reference samples. The software provides results both as values and graphs.

PicoPLEX™ WGA Whole Genome Amplification Kit

PicoPLEX™ WGA is a single cell whole genome amplification kit. It is used when there is not enough DNA available for direct analysis (e.g. for in vitro fertilization applications in single cells).

Based on a reliable amplification technology, the PicoPLEX kit enables quantities of DNA to be extracted from a single cell that previously could be obtained from an average of 10,000 cells. Unlike other amplification methods, PicoPLEX ensures accurate representation of all alleles in cells in a reproducible manner. It can be used for polar bodies, blastomeres, blastocysts for pre-implantation genetic screening and diagnosis.

The use of molecular biology methods in the detection and characterization of microorganisms has revolutionized the field of diagnostic microbiology. The rapid and accurate detection of pathogenic microorganisms by PCR-based methods has eliminated the need for cell culture and enabled results to be obtained in a shorter time. Our solution partner in pathogen detection HEALTH Gene Technologies, has a wide range of products in this field.

SureX® HCV & IL28B Genotyping Multiplex Kit

Hepatitis C virus (HCV) is a highly heterogeneous RNA virus consisting of 6 genotypes and many subtypes. HCV causes chronic hepatitis, which can later develop into liver cirrhosis and even liver cancer. SureX® HCV& IL28B Genotyping Multiplex Kit screens for the 6 most common HCV subtypes and 2 single nucleotide polymorphisms in the gene regulatory region of IL28B that modify drug efficacy. The targets that can be detected with this kit are shown in the table below.

HGT Surex HCV Table

For detailed information about the product, see our current product brochure from here you can download it.

SureX® HPV 25X Genotyping Kit

The human papilloma virus (HPV) consists of low-risk and high-risk HPV types. The low-risk types often do not cause significant disease, while the high-risk types are often associated with cervical cancer. The SureX® HPV 25X Genotyping Kit is intended to detect 25 HPV types with a single test.

For detailed information about the product, see our current product brochure from here you can download it.

SureX® Diarrhea Virus Multiplex Kit

Diarrhea is an intestinal infectious disease that can be caused by many different microorganisms. SureX® Diarrhea Virus Multiplex Kit detects 11 most common diarrhea-causing viruses in a single tube. The target microorganisms that can be detected with this kit are shown in the table below.

hgt_surex-diarrhea

For detailed information about the product, see our current product brochure from here you can download it.

SureX® Rash & Fever Virus Multiplex Kit

SureX® Rash & Fever Virus Multiplex Kit contains 11 different viruses that can cause fever and rash in one go Streptococcus pyogenes and Mycoplasma pneumonia organisms can also be detected. The target microorganisms that can be detected with this kit are shown in the table below.

hgt_surex-rash

For detailed information about the product, see our current product brochure from here you can download it.

SureX® Encephalitis Virus Multiplex Kit

Meningitis can be caused by many different viruses. The main symptoms are fever, headache and meningitis irritation. Approximately % 85~95% of viral meningitis is caused by enterovirus. This is followed by mumps, herpes and adenoviruses. SureX® Encephalitis Virus Multiplex Kit simultaneously examines 20 encephalitis viruses in a single tube. The target viruses that can be detected with this kit are shown in the table below.

hgt_surex_enceph

For detailed information about the product, see our current product brochure from here you can download it.

SureX® Respiratory Infections Multiplex Kit

Akut solunum yolu enfeksiyonlarının neredeyse %95’i ve aşağı solunum yolları hastalıklarının çoğu virüsler nedeniyle meydana gelir. Var olan virüslerin salgınları yeni virüslerin ortaya çıkmasıyla baş edebilmek için hastaların hızlı, hassas ve çok parametreli bir yöntemle test edilmeleri gerekir. Bu sayede uygun tanı konup buna uygun tedaviler gerçekleştirilebilir. SureX® Respiratory Infections Multiplex Kit allows testing of 14 target genes of 13 common respiratory infection viruses in a single tube. The target viruses that can be detected with this kit are shown in the table below.

hgt_surex-resp

 

hgt_surex

A relatively new field, pharmacogenomics is concerned with how a person's genetic makeup influences their response to medicines. It is a combination of pharmacology, the science of drugs, and genomics, the study of genes and their functions. Its aim is to identify effective and safe medicines and appropriate doses in accordance with a person's genetic makeup. Today, medicines are often prescribed on the assumption that they will be effective, but it is not possible to predict who will benefit from a medicine, who will not respond to treatment at all, or who may show some side effects. With the studies conducted in the light of the information obtained from the Human Genome Project, many data are obtained on how the genetic structure of a person will affect the response of that person's body to the drug. The practical effectiveness of these data is being proven more and more every day.

As Kromogen Biotechnology, we have a wide range of products in the field of pharmacogenomics HEALTH Gene Technologies with SureX® pharmacogenomics. For more information on SureX® pharmacogenomics products, see the detailed product brochure. from here you can reach.

SureX® Multiplex Gene Expression Kit for Cancer Drugs

Recent studies have shown that the expression levels of some genes alter the efficacy of related cancer drugs. Determining the expression levels of these genes can be a guide in determining personalized methods in cancer treatment. With the SureX® Multiplex Gene Expression Kit for Cancer Drugs, the expression levels of 14 genes can be determined simultaneously to gain therapeutic insight for more than 20 cancer drugs.

The table below shows the genes and related cancer drugs whose expression levels can be detected with this kit.

hgt_surex-gen

SureX® Platinum-Based Chemotherapy SNP Multiplex Kit

Platinum-based chemotherapy drugs such as carboplatin and oxaliplatin are the most commonly used anti-tumor drugs. Platinum-based drugs can have toxic effects such as hearing loss. The risks of these side effects have been associated with certain genotypes. With SureX® Platinum-Based Chemotherapy SNP Multiplex Kit, a total of 8 single nucleotide polymorphisms (SNPs) can be analyzed in TPMT, ERCC1, XRCC1 and 4 other genes.

The table below shows the single nucleotide polymorphisms that can be screened with this kit.

hgt_surex-platinum

SureX® CYP2C19 Genotyping Kit

CYP2C19 is one of the most important Cytochrome P450 enzymes involved in drug metabolism. SureX® CYP2C19 Genotyping Kit examines three CYP2C19 SNP loci (*2, *3 and *17) in the human genome. Studies have shown that different CYP2C19 genotypes affect enzyme activities, leading to increased or decreased metabolic rate of drugs. Therefore, CYP2C19 genotyping can help doctors predict the efficacy and side effects of certain drugs and determine appropriate medications and dosages.

The table below shows the genotypes that can be screened with this kit and their effects on drug metabolism.

hgt_surex-metab

SureX® ALDH2 /ADH1B Genotyping Kit

Nitroglycerin (NTG) is a vasodilator drug and functions through the release of nitric oxide (NO). This conversion is carried out by the enzyme aldehyde dehydrogenase (encoded by the ALDH2 gene). However, the Glu504Lys mutation in the ALDH2 gene decreases NTG activity by reducing enzyme activity. In addition, alcohol dehydrogenase (encoded by the ADH1B gene) and aldehyde dehydrogenase are key enzymes in alcohol metabolism. Mutations in these two genes affect alcohol metabolism, leading to the accumulation of acetaldehyde and other harmful substances. Therefore, the ALDH2/ADH1B genetic test can also be used to test for healthy alcohol consumption.

The table below shows the genotypes that can be screened with this kit and their effects on drug metabolism.

hgt_surex-aldh2

SureX® Warfarin SNP Multiplex Kit

Warfarin tromboembolik hastalıkların tedavisinde en sık kullanılan antikoagülandır. Warfarin’in klinik etkinliği hastadan hastaya farklılık gösterir ve doz farklılıkları 20 kata kadar çıkabilir. Tedavide dozun doğru belirlenememesi sonucu olarak kanama oldukça sık (hastaların %25’inde) görülür. Kişiler arasındaki farklılıklar ve ilaç yan etkileri CYP2C9 ve VKORC1 genlerinin metabolizmaya etkilerinden kaynaklanmaktadır. SureX® Warfarin SNP Multipleks Kiti ile warfarin metabolizmasıyla ilişkilendirilmiş tek nükleotid polimorfizmlerinin taranması tedavi için ipuçları sağlayarak hastaları yan etkilerden korur.

The table below shows the genes that can be screened with this kit and their effect on warfarin metabolism.

hgt_surex-warfarin

SureX® 5-FU Chemo Guide SNP Multiplex Kit

Fluorouracil (5-FU) is used to treat many cancers, especially cancers of the colon and digestive system. 5-FU, an effective anti-tumor drug, can cause different side effects in different patients. These differences have been found to be caused by a mutation. Loss/reduction of the function of the DPD enzyme as a result of a DYPD mutation can lead to fatal side effects in patients receiving 5-FU treatment. With the SureX® 5-FU Chemotherapy Multiplex Kit, 8 SNPs in 7 cancer-related genes can be screened to predict side effects and adjust the drug dose. These genes are shown in the table below:

hgt_surex-5fu

Every individual is different, and so is their cancer. Nowadays, when personalized treatments are rapidly becoming widespread, it is no longer a dream to treat cancer by taking into account the genetic structure of the person and the type of cancer.

Personal Genome Diagnostics, founded by Johns Hopkins University researchers, of which we are the sole authorized representative, offers personalized cancer genome analysis service packages. The analyzes are aimed at detecting genomic variations that may shed light on the biological basis of cancer. The report generated as a result of the test includes a detailed analysis of the parameters examined, as well as personalized medication and treatment recommendations, including the latest developments in the world.

In addition to tumor tissue analysis, there are different applications for analyzing both specific target regions and all coding regions with non-surgical methods based on the examination of blood samples taken from the patient, also called liquid biopsy.

Cancer Genetics

CancerSelect-R™ 88 Next Generation Sequencing Cancer Panel

This panel examines the 88 best characterized target cancer genes. DNA is isolated from normal and/or tumor samples from the same patient using proprietary methods, including low quality or small quantities of samples. Target regions are amplified using proprietary methods and tumor-specific (somatic) mutations, copy number changes and translocations are detected by high-depth next-generation sequencing. Detailed information about CancerSelect-R™ 88 products from the brochure you can reach.

CancerSelect-R™ 203 Next Generation Sequencing Cancer Panel

Unlike the CancerSelect-R™ 88 panel, this panel examines the 203 best characterized target cancer genes. Detailed information about the product in our brochure you can find.

CancerXome™ Next Generation Sequencing Cancer Panel

CancerXome™ targets and analyzes the coding regions of >20,000 genes. Both tumor and normal samples are prepared using proprietary methods, including low-quality or small-quantity samples. High-depth sequencing detects tumor-specific (somatic) mutations and copy number alterations. Detailed information about this product can be found in the product in our brochure you can find.

ImmunoSelect-R™ Next Generation Sequencing Cancer Panel

Neoantigens are a new class of immunogenic antigens that are completely individual and tumor-specific, present in every patient's tumor. By combining Personal Genome Diagnostics whole exon cancer analysis (CancerXome™) with in-silico neoantigen prediction, ImmunoSelect-R™ identifies and prioritizes the most relevant neoantigens arising from mutations and the resulting data informs adaptive T-cell transfer, cancer vaccine development and prediction of the clinical efficacy of checkpoint inhibitors. More detailed information about ImmunoSelect-R™ can be found in the product from our brochure you can reach.

METDetect-R™ Next Generation Sequencing Cancer Panel

METDetect-R™ analysis, which uses next-generation sequencing to examine the MET tyrosine kinase receptor locus and surrounding regions, is designed to identify mutant alleles to predict response to treatment. By applying this assay to both plasma and tumor tissue samples, MET amplification can be detected in only a very small percentage of DNA molecules (% 0.1). For more information product brochure you can examine.

PlasmaSelect-R™ Next Generation Sequencing Cancer Panel

PlasmaSelect-R™ examines circulating tumor cells to help identify cancer-causing genetic changes without the need for invasive biopsy methods or tumor tissue. PlasmaSelect-R™ examines 63 well-characterized cancer genes. Free circulating tumor DNA is separated from plasma using proprietary methods that enable the extraction of small amounts of DNA. Target regions are amplified using proprietary methods and tumor-specific (somatic) mutations and translocations are identified with high sensitivity and accuracy by high-depth next-generation sequencing. For detailed information about PlasmaSelect-R™ our brochure you can apply.

LungSelect™ Next Generation Sequencing Cancer Panel

LungSelect™ is used to identify the most common somatic mutations and translocations in the plasma of patients with non-small cell lung cancer that allow for clinical intervention. LungSelect™ screens for all of the alterations specified in the guidelines for FDA-approved therapies. For more information, see our product brochure from here you can reach.

Customized Solutions

In addition to these products, PDGx also offers customized solutions. Please contact us for more information.

PerkinElmer Prenatal BoBs™

Prenatal BoBs™ is a CE-IVD marked product for prenatal diagnosis. In addition to detecting copy number variations on chromosomes 13, 18, 21, X and Y, the product also enables the detection of 9 additional chromosomal regions whose absence has been shown to lead to poor outcomes. Changes in these targeted regions can easily be missed by other commonly used methods.